Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Study summary

This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedRYZ101 Dose Level 1 and RYZ101 Dose Level 2

Plus 5 other study approaches.

Who it may be forSmall cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 13, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 1

Interventional

Where is it offered?13 U.S. locations

Locations may change over time.

Who runs it?RayzeBio, Inc.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: RayzeBio, Inc.
Interventions being studied: Drug: RYZ101 Dose Level 1; Drug: RYZ101 Dose Level 2; Drug: RYZ101 Dose Level 3; Drug: RYZ101 Dose Level -1; Drug: Atezolizumab; Drug: Carboplatin; Drug: Etoposide

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Small cell lung cancer (SCLC)→

Treatment approach

Immunotherapy→Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Age of at least 18 years at the time of signing the informed consent.
Cytologically or histologically confirmed ES-SCLC (American Joint Committee on Cancer \[AJCC\] 8th edition) and is untreated or received ≤1 cycle of platinum-etoposide and PD-L1 inhibitor therapy. It is acceptable to omit the first dose of PD-L1 inhibitor therapy due to logistical reasons if receiving SoC during or prior to the start of the screening period.
Subject is a candidate for therapy with SoC which includes:
Carboplatin for a maximum of 4 cycles
Etoposide for a maximum of 4 cycles
Atezolizumab
At least 1SSTR-PET imaging-positive measurable site of disease (according to RECIST v1.1) and ≥50% of RECIST v1.1 measurable metastatic lesions must be SSTR-imaging positive.
Adequate hematologic, renal and hepatic function

Reasons someone may not be able to joinExclusion criteria

Prior exposure to immune-mediated therapy,
Known active or suspected autoimmune disease or any condition requiring systemic treatment with immunosuppressive medications within 14 days prior to first dose of study drug
History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis. Note: History of radiation pneumonitis is permitted.
Severe infection within 4 weeks and/or treatment with therapeutic oral or i.v. antibiotics within 2 weeks prior to initiation of study treatment.
Prior allogeneic stem cell or solid organ transplantation.
Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab.
Radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy. Radiation therapy outside of the chest for palliative care is allowed but must be completed \>2 weeks prior to first dose of study drug.
Significant cardiovascular disease and/or resistant hypertension
Subjects with previously treated central nervous system (CNS) metastases who have not recovered from acute side effects of radiotherapy.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Research FacilityLos Angeles, California
Research FacilitySan Francisco, California
Research FacilityJacksonville, Florida
Research FacilityMiami, Florida
Research FacilityOrlando, Florida
Research FacilityIowa City, Iowa
Reserach FacilityLexington, Kentucky
Research FacilityGrand Rapids, Michigan
Research FacilityRochester, Minnesota
Research FacilitySt Louis, Missouri
Research FacilityOmaha, Nebraska
Research FacilitySalt Lake City, Utah

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 13, 2026. Always confirm current availability with the study team.

View original record ↗